Matsushita IMP Building, 1-3-7, Shiromi,
Chuo-ku, Osaka, 540-0001, Japan
Japan
Telephone:
81-6-69491-1496
E-mail Address:
Takanori Abe
Areas of Expertise
Patents, Trademarks, Copyright, IP Litigation, Pharma & Biotech
Overview
In 2024, Abe & Partners experienced a bountiful year with four successful decisions and zero losses. Notably, we achieved victories representing various pharmaceutical giants. Abe & Partners notably secured a triumph for a Japanese pharmaceutical company by invalidating all claims of an Indian pharmaceutical company’s patent linked to the Zika virus vaccine.
Additionally, we represented a U.S. pharmaceutical company, overturning the JPO’s cancellation notice and maintaining the patent’s claims unaltered. Furthermore, in a significant legal battle representing Bayer Healthcare and Regeneron Pharmaceuticals against Samsung Bioepis, Abe & Partners effectively quashed Samsung Bioepis’ unfair competition claim. The Regeneron case was concluded with a dismissal decision by the IP High Court in 2025. These cases form part of a broader global litigation landscape between Regeneron/Bayer and biosimilar companies concerning Eylea, a prominent biopharmaceutical medicinal drug.